{"doi":"10.14814/phy2.15859","title":"Effects of acute aerobic exercise on circulating <scp>sTLR</scp> and <scp>sRAGE</scp> profiles in normal‐ and abnormal<scp>‐</scp>glucose‐tolerant individuals","abstract":"Abstract BMI‐matched normal‐ (NGT, n = 10, 41 ± 4y, 35.6 ± 3.0 kg/m 2 ) and abnormal‐glucose‐tolerant (AGT, n = 16, 51 ± 3y, 34.3 ± 1.5 kg/m 2 ) participants were evaluated for body composition, metabolic health (oral glucose tolerance test [OGTT]), and VO 2 max. Participants also completed a treadmill walking test at 65% VO 2 max for 30 min. Total sRAGE, esRAGE, sTLR2, and sTLR4 were assessed via ELISA, and cRAGE was calculated. AGT exhibited greater ( p &lt; 0.05) body fat % (+24%), fasting plasma glucose (+37%), OGTT AUC (+59%), and HOMA‐IR (+55%) and lower ( p &lt; 0.05) VO 2 max (−24%). sTLR2 was 33% lower in AGT than NGT (main effect, p = 0.034). However, sTLR2 did not change ( p &gt; 0.05) following AE. sTLR4 tended to be 36% lower in AGT than NGT (main effect, p = 0.096) and did not change following AE ( p &gt; 0.05). Total sRAGE and isoforms were similar ( p &gt; 0.05) between groups and did not change following AE ( p &gt; 0.05). sTLR2 was correlated with ( p &lt; 0.05) basal BG ( r = −0.505) and OGTT AUC ( r = −0.687). sTLR4 was correlated with basal BG ( p &lt; 0.10, r = −0.374) and OGTT AUC ( p &lt; 0.05, r = −0.402). Linear regressions were predictive of sTLRs in the basal state (sTLR2: R 2 = 0.641, p = 0.01; sTLR4: R 2 = 0.566, p = 0.037) and after acute exercise state (sTLR2: R 2 = 0.681, p = 0.004, sTLR4: R 2 = 0.568, p = 0.036).These findings show circulating sTLR profiles are disrupted in AGT and acute AE minimally modulates their levels.","journal":"Physiological Reports","year":2023,"id":373842,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7172,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":736220,"name":"Edwin R. Miranda","orcid":"0000-0003-2370-4118","position":1,"is_corresponding":false},{"id":248576,"name":"Pallavi Varshney","orcid":null,"position":2,"is_corresponding":false},{"id":627509,"name":"Sarah S. Farabi","orcid":"0000-0002-4586-2283","position":3,"is_corresponding":false},{"id":791708,"name":"Lauretta Quinn","orcid":null,"position":4,"is_corresponding":false},{"id":493623,"name":"Jacob M. Haus","orcid":"0000-0002-8048-2470","position":5,"is_corresponding":false},{"id":778510,"name":"Ryan K. Perkins","orcid":"0000-0002-2546-4085","position":0,"is_corresponding":true}],"reference_count":67,"raw_metadata":null,"created_at":"2026-07-19T01:16:07.080027Z","pmid":"37985201","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}